Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.

Abstract

WHAT IS KNOWN AND BACKGROUND  For relapsed or refractory multiple myeloma (RRMM), a series of novel agents (thalidomide, bortezomib and lenalidomide) has emerged during the latest decade, but their use in routine clinical practice is not well documented as well as the cost of RRMM. OBJECTIVE Our aim is to review the therapeutic management of such patients… (More)
DOI: 10.1111/j.1365-2710.2009.01153.x

Topics

Cite this paper

@article{Armoiry2011ManagementOR, title={Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.}, author={X Armoiry and Francis L Fagnani and Lotfi Benboubker and Thierry Facon and J Paul Fermand and Cyrille Hulin and Philippe Moreau and G Aulagner}, journal={Journal of clinical pharmacy and therapeutics}, year={2011}, volume={36 1}, pages={19-26} }